<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DrugDDI.d237" origId="Leflunomide"><sentence id="DrugDDI.d237.s0" origId="s0" text="Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration ."><entity charOffset="0-14" id="DrugDDI.d237.s0.e0" origId="s0.p0" text="Cholestyramine" type="drug"/><entity charOffset="19-27" id="DrugDDI.d237.s0.e1" origId="s0.p2" text="Charcoal" type="drug"/><entity charOffset="46-60" id="DrugDDI.d237.s0.e2" origId="s0.p3" text="cholestyramine" type="drug"/><entity charOffset="64-82" id="DrugDDI.d237.s0.e3" origId="s0.p5" text="activated charcoal" type="drug"/><entity charOffset="187-204" id="DrugDDI.d237.s0.e4" origId="s0.p21" text="active metabolite" type="drug"/><entity charOffset="208-219" id="DrugDDI.d237.s0.e5" origId="s0.p22" text="leflunomide" type="drug"/><pair e1="DrugDDI.d237.s0.e0" e2="DrugDDI.d237.s0.e1" id="DrugDDI.d237.s0.p0" interaction="false"/><pair e1="DrugDDI.d237.s0.e0" e2="DrugDDI.d237.s0.e2" id="DrugDDI.d237.s0.p1" interaction="true"/><pair e1="DrugDDI.d237.s0.e0" e2="DrugDDI.d237.s0.e3" id="DrugDDI.d237.s0.p2" interaction="false"/><pair e1="DrugDDI.d237.s0.e0" e2="DrugDDI.d237.s0.e4" id="DrugDDI.d237.s0.p3" interaction="false"/><pair e1="DrugDDI.d237.s0.e0" e2="DrugDDI.d237.s0.e5" id="DrugDDI.d237.s0.p4" interaction="false"/><pair e1="DrugDDI.d237.s0.e1" e2="DrugDDI.d237.s0.e2" id="DrugDDI.d237.s0.p5" interaction="false"/><pair e1="DrugDDI.d237.s0.e1" e2="DrugDDI.d237.s0.e3" id="DrugDDI.d237.s0.p6" interaction="false"/><pair e1="DrugDDI.d237.s0.e1" e2="DrugDDI.d237.s0.e4" id="DrugDDI.d237.s0.p7" interaction="false"/><pair e1="DrugDDI.d237.s0.e1" e2="DrugDDI.d237.s0.e5" id="DrugDDI.d237.s0.p8" interaction="false"/><pair e1="DrugDDI.d237.s0.e2" e2="DrugDDI.d237.s0.e3" id="DrugDDI.d237.s0.p9" interaction="false"/><pair e1="DrugDDI.d237.s0.e2" e2="DrugDDI.d237.s0.e4" id="DrugDDI.d237.s0.p10" interaction="false"/><pair e1="DrugDDI.d237.s0.e2" e2="DrugDDI.d237.s0.e5" id="DrugDDI.d237.s0.p11" interaction="false"/><pair e1="DrugDDI.d237.s0.e3" e2="DrugDDI.d237.s0.e4" id="DrugDDI.d237.s0.p12" interaction="false"/><pair e1="DrugDDI.d237.s0.e3" e2="DrugDDI.d237.s0.e5" id="DrugDDI.d237.s0.p13" interaction="false"/><pair e1="DrugDDI.d237.s0.e4" e2="DrugDDI.d237.s0.e5" id="DrugDDI.d237.s0.p14" interaction="false"/></sentence><sentence id="DrugDDI.d237.s1" origId="s1" text="Hepatotoxic Drugs Increased side effects may occur when leflunomide is given concomitantly with hepatotoxic substances."><entity charOffset="12-17" id="DrugDDI.d237.s1.e0" origId="s1.p25" text="Drugs" type="drug"/><entity charOffset="56-67" id="DrugDDI.d237.s1.e1" origId="s1.p31" text="leflunomide" type="drug"/><pair e1="DrugDDI.d237.s1.e0" e2="DrugDDI.d237.s1.e1" id="DrugDDI.d237.s1.p0" interaction="true"/></sentence><sentence id="DrugDDI.d237.s2" origId="s2" text="This is also to be considered when leflunomide treatment is followed by such drugs without a drug elimination procedure."><entity charOffset="35-46" id="DrugDDI.d237.s2.e0" origId="s2.p42" text="leflunomide" type="drug"/><entity charOffset="77-82" id="DrugDDI.d237.s2.e1" origId="s2.p45" text="drugs" type="drug"/><pair e1="DrugDDI.d237.s2.e0" e2="DrugDDI.d237.s2.e1" id="DrugDDI.d237.s2.p0" interaction="false"/><negationtags>This is also to be considered when leflunomide treatment is followed by such drugs &lt;xcope&gt;&lt;cue&gt;without&lt;/cue&gt; a drug elimination procedure&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d237.s3" origId="s3" text="In a small (n=30) combination study of ARAVA with methotrexate, a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients."><entity charOffset="39-44" id="DrugDDI.d237.s3.e0" origId="s3.p52" text="ARAVA" type="drug"/><entity charOffset="50-62" id="DrugDDI.d237.s3.e1" origId="s3.p53" text="methotrexate" type="drug"/><entity charOffset="92-105" id="DrugDDI.d237.s3.e2" origId="s3.p56" text="liver enzymes" type="drug"/><pair e1="DrugDDI.d237.s3.e0" e2="DrugDDI.d237.s3.e1" id="DrugDDI.d237.s3.p0" interaction="true"/><pair e1="DrugDDI.d237.s3.e0" e2="DrugDDI.d237.s3.e2" id="DrugDDI.d237.s3.p1" interaction="false"/><pair e1="DrugDDI.d237.s3.e1" e2="DrugDDI.d237.s3.e2" id="DrugDDI.d237.s3.p2" interaction="false"/></sentence><sentence id="DrugDDI.d237.s4" origId="s4" text="All elevations resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide."><entity charOffset="53-58" id="DrugDDI.d237.s4.e0" origId="s4.p68" text="drugs" type="drug"/><entity charOffset="90-101" id="DrugDDI.d237.s4.e1" origId="s4.p72" text="leflunomide" type="drug"/><pair e1="DrugDDI.d237.s4.e0" e2="DrugDDI.d237.s4.e1" id="DrugDDI.d237.s4.p0" interaction="false"/></sentence><sentence id="DrugDDI.d237.s5" origId="s5" text="A  3-fold increase was seen in another 5 patients."/><sentence id="DrugDDI.d237.s6" origId="s6" text="All of these also resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide."><entity charOffset="56-61" id="DrugDDI.d237.s6.e0" origId="s6.p85" text="drugs" type="drug"/><entity charOffset="93-104" id="DrugDDI.d237.s6.e1" origId="s6.p89" text="leflunomide" type="drug"/><pair e1="DrugDDI.d237.s6.e0" e2="DrugDDI.d237.s6.e1" id="DrugDDI.d237.s6.p0" interaction="false"/></sentence><sentence id="DrugDDI.d237.s7" origId="s7" text="Three patients met ACR criteria for liver biopsy (1: Roegnik Grade I, 2: Roegnik Grade IIIa)."><entity charOffset="15-18" id="DrugDDI.d237.s7.e0" origId="s7.p91" text="met" type="drug"/></sentence><sentence id="DrugDDI.d237.s8" origId="s8" text="No pharmacokinetic interaction was identified."><negationtags>&lt;xcope&gt;&lt;cue&gt;No&lt;/cue&gt; pharmacokinetic interaction was identified&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d237.s9" origId="s9" text="NSAIDs In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of diclofenac and ibuprofen at concentrations in the clinical range."><entity charOffset="0-6" id="DrugDDI.d237.s9.e0" origId="s9.p105" text="NSAIDs" type="drug"/><entity charOffset="106-116" id="DrugDDI.d237.s9.e1" origId="s9.p116" text="diclofenac" type="drug"/><entity charOffset="121-130" id="DrugDDI.d237.s9.e2" origId="s9.p118" text="ibuprofen" type="drug"/><pair e1="DrugDDI.d237.s9.e0" e2="DrugDDI.d237.s9.e1" id="DrugDDI.d237.s9.p0" interaction="false"/><pair e1="DrugDDI.d237.s9.e0" e2="DrugDDI.d237.s9.e2" id="DrugDDI.d237.s9.p1" interaction="false"/><pair e1="DrugDDI.d237.s9.e1" e2="DrugDDI.d237.s9.e2" id="DrugDDI.d237.s9.p2" interaction="true"/></sentence><sentence id="DrugDDI.d237.s10" origId="s10" text="The clinical significance of this finding is unknown;"/><sentence id="DrugDDI.d237.s11" origId="s11" text="however, there was extensive concomitant use of NSAIDs in clinical studies and no differential effect was observed."><entity charOffset="48-54" id="DrugDDI.d237.s11.e0" origId="s11.p130" text="NSAIDs" type="drug"/><negationtags>however, there was extensive concomitant use of NSAIDs in clinical studies and &lt;xcope&gt;&lt;cue&gt;no&lt;/cue&gt; differential effect was observed&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d237.s12" origId="s12" text="Tolbutamide In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of tolbutamide at concentrations in the clinical range."><entity charOffset="0-11" id="DrugDDI.d237.s12.e0" origId="s12.p136" text="Tolbutamide" type="drug"/><entity charOffset="111-122" id="DrugDDI.d237.s12.e1" origId="s12.p147" text="tolbutamide" type="drug"/><pair e1="DrugDDI.d237.s12.e0" e2="DrugDDI.d237.s12.e1" id="DrugDDI.d237.s12.p0" interaction="false"/></sentence><sentence id="DrugDDI.d237.s13" origId="s13" text="The clinical significance of this finding is unknown."/><sentence id="DrugDDI.d237.s14" origId="s14" text="Rifampin Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone."><entity charOffset="0-8" id="DrugDDI.d237.s14.e0" origId="s14.p154" text="Rifampin" type="drug"/><entity charOffset="66-71" id="DrugDDI.d237.s14.e1" origId="s14.p158" text="ARAVA" type="drug"/><entity charOffset="112-120" id="DrugDDI.d237.s14.e2" origId="s14.p162" text="rifampin" type="drug"/><entity charOffset="180-185" id="DrugDDI.d237.s14.e3" origId="s14.p172" text="ARAVA" type="drug"/><pair e1="DrugDDI.d237.s14.e0" e2="DrugDDI.d237.s14.e1" id="DrugDDI.d237.s14.p0" interaction="false"/><pair e1="DrugDDI.d237.s14.e0" e2="DrugDDI.d237.s14.e2" id="DrugDDI.d237.s14.p1" interaction="false"/><pair e1="DrugDDI.d237.s14.e0" e2="DrugDDI.d237.s14.e3" id="DrugDDI.d237.s14.p2" interaction="false"/><pair e1="DrugDDI.d237.s14.e1" e2="DrugDDI.d237.s14.e2" id="DrugDDI.d237.s14.p3" interaction="true"/><pair e1="DrugDDI.d237.s14.e1" e2="DrugDDI.d237.s14.e3" id="DrugDDI.d237.s14.p4" interaction="false"/><pair e1="DrugDDI.d237.s14.e2" e2="DrugDDI.d237.s14.e3" id="DrugDDI.d237.s14.p5" interaction="false"/></sentence><sentence id="DrugDDI.d237.s15" origId="s15" text="Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin."><entity charOffset="29-34" id="DrugDDI.d237.s15.e0" origId="s15.p177" text="ARAVA" type="drug"/><entity charOffset="148-153" id="DrugDDI.d237.s15.e1" origId="s15.p192" text="ARAVA" type="drug"/><entity charOffset="158-166" id="DrugDDI.d237.s15.e2" origId="s15.p194" text="rifampin" type="drug"/><pair e1="DrugDDI.d237.s15.e0" e2="DrugDDI.d237.s15.e1" id="DrugDDI.d237.s15.p0" interaction="false"/><pair e1="DrugDDI.d237.s15.e0" e2="DrugDDI.d237.s15.e2" id="DrugDDI.d237.s15.p1" interaction="false"/><pair e1="DrugDDI.d237.s15.e1" e2="DrugDDI.d237.s15.e2" id="DrugDDI.d237.s15.p2" interaction="true"/></sentence><sentence id="DrugDDI.d237.s16" origId="s16" text="Warfarin Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported."><entity charOffset="0-8" id="DrugDDI.d237.s16.e0" origId="s16.p195" text="Warfarin" type="drug"/><entity charOffset="61-66" id="DrugDDI.d237.s16.e1" origId="s16.p202" text="ARAVA" type="drug"/><entity charOffset="71-79" id="DrugDDI.d237.s16.e2" origId="s16.p204" text="warfarin" type="drug"/><pair e1="DrugDDI.d237.s16.e0" e2="DrugDDI.d237.s16.e1" id="DrugDDI.d237.s16.p0" interaction="false"/><pair e1="DrugDDI.d237.s16.e0" e2="DrugDDI.d237.s16.e2" id="DrugDDI.d237.s16.p1" interaction="false"/><pair e1="DrugDDI.d237.s16.e1" e2="DrugDDI.d237.s16.e2" id="DrugDDI.d237.s16.p2" interaction="true"/></sentence></document>